Document is current
Any future updates will be listed below
-
Authors
Bodmer, Nicolas S. https://orcid.org/0000-0001-5296-4109
Faes, Livia https://orcid.org/0000-0002-4159-3960
Gross, Nico
Bachmann, Lucas M. https://orcid.org/0000-0002-9868-154X
Huber, Carola
Näpflin, Markus
Schmid, Martin K. https://orcid.org/0000-0002-1618-9552
- License Information
-
More Information
Article History
Received: 26 September 2025
Revised: 30 January 2026
Accepted: 11 February 2026
First Online: 24 February 2026
Competing interests
: LMB is CEO of Oculocare Medical Inc. LF has received research support from Bayer AG, F. Hoffmann-La Roche AG and AbbVie, and meetings and travel support from Apellis Pharmaceuticals Inc.
: For the clinical dataset, inclusion required documented general consent allowing secondary research use of health data. Analysis of the insurance claims dataset used anonymised data, so informed consent was not required. For LUKS patients with linked health insurance claims, an exemption was granted according to Article 34 of the Swiss Human Research Act (HRA).
